Literature DB >> 2432126

Different functional sites on rIFN-alpha 2 and their relation to the cellular receptor binding site.

M Cebrián, E Yagüe, M O de Landázuri, M Rodíguez-Moya, M Fresno, N Pezzi, S Llamazares, F Sánchez-Madrid.   

Abstract

Functional domains on the recombinant interferon-alpha 2 (rIFN-alpha 2) molecule, which are involved in antiviral and NK enhancing activities, have been defined by immunochemical mapping with MAb, and their relationship with the IFN cellular receptor binding site has been studied. With 20 different anti-IFN-alpha 2 MAb selected by their binding to 125I-labeled IFN and by immunoprecipitation of the 20 Kd IFN molecule, we have defined three spatially separated epitopes (designated as sites A, B, and C) and two partially overlapping antigenic determinants on the IFN-alpha 2 molecule. Functional relation of IFN-alpha 2 A, B, and C epitopes have been determined by assaying the effect of various anti-IFN MAb on IFN-mediated biologic activities. MAb directed to sites A and B neutralized the antiviral activity of IFN. Furthermore, the MAb specific for site B displayed a neutralizing potency threefold higher than MAb directed to site A. Site B was also involved in the enhancing activity of IFN on NK-mediated cell cytotoxicity, whereas site A was not. MAb directed to site C partially affected the IFN-boosted NK activity but did not neutralize the IFN antiviral activity. Inhibition studies of 125I-IFN binding to human U-937 myelomonocytic cells by anti-IFN MAb demonstrated that MAb directed to site B blocked different IFN biologic functions by preventing its binding to the cellular receptor, whereas MAb directed to sites A and C caused no inhibition and partial inhibition of this binding, respectively.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

Review 1.  The cellular receptor of the alpha-beta interferons.

Authors:  K E Mogensen; G Uzé; P Eid
Journal:  Experientia       Date:  1989-06-15

Review 2.  Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.

Authors:  Kenji Oritani; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 3.  Alpha interferon as an immunomodulator in the treatment of patients with tumors.

Authors:  M Alvarez-Mon; O J Salmerón; L Manzano; M Rodríguez-Zapata; E Reyes; L M Vaquer; J Carballido
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

4.  Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1.

Authors:  Shin-Ichiro Kawamoto; Kenji Oritani; Hideo Asada; Isao Takahashi; Jun Ishikawa; Hitoshi Yoshida; Masahide Yamada; Naoko Ishida; Hidetoshi Ujiie; Hiroaki Masaie; Yoshiaki Tomiyama; Yuji Matsuzawa
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis.

Authors:  R González-Amaro; C García-Monzón; L García-Buey; R Moreno-Otero; J L Alonso; E Yagüe; J P Pivel; M López-Cabrera; E Fernández-Ruiz; F Sánchez-Madrid
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.